{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-23-024370","form_type":"8-K","ticker":"VTGN","cik":"0001411685","company_name":"Vistagen Therapeutics, Inc.","filed_at":"2023-08-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.837051+00:00","generated_at":"2026-06-11T05:30:47.800614+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Vistagen appoints Cindy Anderson as CFO; Jerrold Dotson retires after decade-long tenure","bullets":["Cindy Anderson appointed CFO effective August 21, 2023, succeeding Jerrold Dotson upon his planned retirement.","Anderson brings 15+ years biopharma experience, most recently Chief Accounting Officer at Alnylam Pharmaceuticals (ALNY).","She previously held senior finance roles at Alexion Pharmaceuticals and began her career at PwC and EY.","No arrangements or related-party transactions exist in connection with Anderson's appointment.","CEO Shawn Singh expressed gratitude for Dotson's decade of service and welcomed Anderson's financial expertise."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-23-024370","json":"https://secwatch.observer/filing/0001437749-23-024370.json","markdown":"https://secwatch.observer/filing/0001437749-23-024370.md","text":"https://secwatch.observer/filing/0001437749-23-024370.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1411685/000143774923024370/0001437749-23-024370-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1411685/000143774923024370/vtgn20230821_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T05:30:47.800614+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4677d2abfd","claim":"Cynthia Anderson was appointed as Chief Financial Officer at Vistagen Therapeutics, Inc..","evidence_excerpt":"announced the appointment of Ms. Cynthia Anderson, C.P.A., as the Company’s Chief Financial Officer","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1411685/000143774923024370/0001437749-23-024370-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"ea57e305c8","claim":"Jerrold Dotson retired as Chief Financial Officer at Vistagen Therapeutics, Inc..","evidence_excerpt":"Ms. Anderson replaces Mr. Jerrold Dotson upon his retirement, effective August 21, 2023","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1411685/000143774923024370/0001437749-23-024370-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"retired"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}